Mandelic AcidvsRetinaldehyde

Mandelic acid (152 Da, the largest common AHA) exfoliates through calcium chelation and corneodesmosome disruption like other AHAs, but its large molecular size results in slower, more even epidermal penetration with reduced risk of hot-spot irritation and stratum corneum over-exfoliation. Its phenyl ring confers partial lipophilicity, enabling penetration into the pilosebaceous unit and follicular infundibulum—unlike purely hydrophilic glycolic and lactic acids. Within pores, mandelic acid exerts mild comedolytic effects by disrupting keratinocyte cohesion in the follicular epithelium, similar to salicylic acid. It demonstrates antibacterial activity against Cutibacterium acnes (Propionibacterium acnes) through membrane disruption. Mandelic acid also inhibits tyrosinase and reduces melanosome transfer to keratinocytes, providing brightening benefits. This profile makes it particularly suitable for acne-prone skin, hyperpigmentation, and darker skin tones (Fitzpatrick IV–VI) where gentler exfoliation minimizes post-inflammatory hyperpigmentation risk.

Retinaldehyde is converted to retinoic acid by retinaldehyde dehydrogenase (RALDH) in a single enzymatic step within keratinocytes and fibroblasts. This makes it more potent than retinol (which requires alcohol dehydrogenase then RALDH) but less irritating than tretinoin (the active form). The single-step conversion produces a more controlled retinoic acid flux, reducing RAR-mediated irritation while still activating collagen synthesis, normalizing keratinocyte differentiation, and inhibiting matrix metalloproteinases. It uniquely has direct antimicrobial activity against Cutibacterium acnes through disruption of bacterial membrane integrity and interference with bacterial fatty acid metabolism — no other retinoid has this property. Clinically, this dual mechanism addresses both acne pathogenesis and photoaging.